As per MRFR analysis, the South Korea Cancer Supportive Care Market Size was estimated at 510 (USD Million) in 2023. The South Korea Cancer Supportive Care Market Industry is expected to grow from 522.75(USD Million) in 2024 to 876.25 (USD Million) by 2035. The South Korea Cancer Supportive Care Market CAGR (growth rate) is expected to be around 4.808% during the forecast period (2025 - 2035).
The South Korea Cancer Supportive Care Market is undergoing a number of significant trends that are indicative of the evolving attitudes and requirements regarding cancer care in the region. The rising incidence of cancer in South Korea is a significant factor that has resulted in a greater demand for supportive care services. Healthcare providers have been compelled to broaden their services by this increase, incorporating comprehensive strategies that not only address patients' physical requirements but also their emotional and psychological well-being. Additionally, the South Korean government has been a proponent of initiatives to enhance cancer care, including the provision of educational programs and palliative services to both patients and healthcare professionals.
The market is ripe with opportunities, as there is a growing emphasis on personalised care plans and the integration of technology like telemedicine. This method enables patients to receive quality care from the convenience of their homes, as it enables more personalised support. In addition, the development of alternative approaches that can complement conventional treatments is being facilitated by advancements in integrative therapy research, which has been shown to be advantageous for the overall health of patients. Recently, there has been an increase in the collaboration between healthcare institutions and non-profit organisations with the objective of enhancing support networks for patients and increasing awareness of cancer.
This collaborative mentality cultivates a sense of community in the context of cancer care, enabling patients to exchange experiences and obtain assistance. The stigma associated with obtaining supportive care is diminishing as a result of ongoing public education campaigns that address misconceptions and biases regarding cancer, and this is fostering a more open environment for treatment. In general, these trends demonstrate a progressive transition in the South Korean Cancer Supportive Care Market towards more comprehensive, accessible, and patient-centered approaches.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Increasing Incidence of Cancer in South Korea
The rising number of cancer cases in South Korea is a significant driver for the South Korea Cancer Supportive Care Market Industry. According to the Korea Central Cancer Registry, the number of cancer cases reached approximately 240,000 in 2020, with projections indicating an increase to around 300,000 cases by 2025. This translates to an increase of roughly 25% in just five years. Lifestyle changes, such as increased smoking rates and dietary habits, largely influence this alarming trend.The Ministry of Health and Welfare in South Korea has recognized the critical need for enhanced supportive care services, which further underscores the potential for growth in the cancer supportive care market. Major healthcare institutions, including Seoul National University Hospital and Samsung Medical Center, are already responding to this rising prevalence by expanding their supportive care programs, which will ultimately drive market demand.
Government Initiatives and Funding
The South Korean government has been actively investing in cancer care initiatives, which include supportive care. The National Health Insurance Service (NHIS) has increased subsidies for cancer patients by 30% in 2021, aimed at improving the quality of life and access to supportive care services. This funding is expected to extend to various support services, such as pain management and psychological counseling. With the South Korean government's commitment to improving cancer treatment frameworks, the market for cancer supportive care is poised for impressive growth, as it aligns with national health objectives of enhancing survival rates and patient well-being.
Rising Demand for Holistic Care Approaches
There is a growing trend in South Korea towards holistic care methodologies for cancer patients that not only address the physical aspects of the disease but also the psychological, emotional, and social components. According to the Korean Society of Clinical Oncology, approximately 70% of cancer patients report experiencing anxiety and depression related to their illness, driving demand for comprehensive supportive care services. As more healthcare providers begin to recognize the importance of addressing these psychological aspects through integrated supportive care, this shift is expected to significantly fuel the growth of the South Korea Cancer Supportive Care Market Industry, providing opportunities for healthcare providers to differentiate their services.
Advancements in Cancer Research and Treatment
Technological advancements in cancer treatment methodologies, such as immunotherapy and precision medicine, are revolutionizing the field of oncology in South Korea. As new treatments emerge, the need for supportive care services that cater specifically to the side effects and challenges associated with these advanced therapies is increasing. Reports from the Korea Health Industry Development Institute indicate that the market for cancer therapeutics has consistently grown at a rate of 10% per annum, leading to complex cases that will require heightened supportive care.Established institutions like the National Cancer Center in South Korea are at the forefront of this change, providing an avenue for the growth of supportive care services that cater to modern treatment protocols.
The South Korea Cancer Supportive Care Market offers a comprehensive range of treatment options focused on alleviating the symptoms and side effects of cancer and its therapies. This market is segmented into various types, each playing a critical role in improving patient quality of life. Among these segments, Erythropoiesis-Stimulating Agents (ESA) are significant as they are instrumental in managing anemia associated with chemotherapy, helping enhance hemoglobin levels and reducing fatigue experienced by patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are also crucial, as they support the recovery of blood cell levels after chemotherapy, thereby reducing the risk of infection, a common concern in cancer treatments.
Antiemetics act to prevent nausea and vomiting, which are often side effects of chemotherapy, proving essential for patient comfort and adherence to treatment regimens. Bisphosphonates address bone health issues, particularly in cancer types that lead to bone weakness; they aid in preventing skeletal-related events and thus are vital in supportive care. Opioids are frequently utilized for pain management, addressing a significant symptom for many cancer patients, ensuring they maintain a better quality of life throughout their treatment journey.Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) play a supportive role in alleviating pain and inflammation without the side effects associated with stronger opioids.
Additionally, the 'Others' category encompasses innovative therapies that may arise as healthcare progresses, demonstrating the industry's flexibility and responsiveness to emerging patient needs. Overall, the South Korea Cancer Supportive Care Market segmentation reflects an integrated approach to cancer treatment, focusing on the holistic well-being of patients and improving their overall healthcare experience. As the aging population in South Korea increases and with rising cancer incidence, these segments are poised to expand further, with continuous developments aimed at enhancing therapeutic outcomes for patients battling cancer.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South Korea Cancer Supportive Care Market exhibits a diverse range of applications, reflecting the increasing complexity of cancer care management in the country. A significant portion of this market is attributed to breast cancer, which remains one of the most prevalent forms of cancer among women in South Korea, highlighting the urgent need for supportive care services. Meanwhile, lung cancer stands as another leading application, propelled by high smoking rates and environmental factors, increasing the demand for effective supportive care solutions.Colorectal cancer has also gained prominence, necessitating targeted interventions that address both treatment side effects and quality of life enhancements.
Prostate cancer is increasingly recognized, particularly among aging populations, which calls for enhanced supportive care tailored to male patients. Liver and stomach cancers, common in South Korea, indicate a critical need for specialized care to mitigate symptoms and improve patient outcomes. Other cancers have their distinct sociodemographic influences, further diversifying the Application landscape.With governmental focus on improving cancer care and a growing healthcare infrastructure, the South Korea Cancer Supportive Care Market is poised for significant advancements, fostering a more inclusive and effective approach to cancer management across all applications.
The Distribution Channel segment of the South Korea Cancer Supportive Care Market plays a critical role in ensuring that patients have access to essential supportive care products. This segment encompasses various channels, including Hospital Pharmacies, Drug Stores, Retail Pharmacies, and Online Providers. Hospital Pharmacies are particularly significant as they provide tailored medications and support directly within healthcare facilities, facilitating immediate patient care. Drug Stores and Retail Pharmacies contribute a vast network for patient accessibility, handling a wide range of products to meet the needs of cancer patients.
Online Providers have gained increasing traction due to the convenience of home delivery and direct access to specialized products. This shift towards online channels is notable in South Korea, driven by a tech-savvy population and increasing digital health trends. The overall landscape of the South Korea Cancer Supportive Care Market reflects an evolving approach to healthcare, with each distribution channel adapting to fulfill the needs of the population effectively. This diversification in distribution strategy enhances patient experience and ensures that vital care solutions remain within reach for those undergoing cancer treatment.
The South Korea Cancer Supportive Care Market is rapidly evolving, reflecting the growing acknowledgment of the critical need for supportive care services in oncology. This market focuses on enhancing patients' quality of life and addressing the side effects of cancer treatments. Factors such as an increasing incidence of cancer, advancing treatment options, and a greater emphasis on palliative care have contributed to the growth of this sector. The competitive landscape is characterized by a mix of local firms and international players, each seeking to enhance their product offerings and improve patient experiences. Key trends involve the adoption of advanced technologies, the integration of novel therapeutics, and a patient-centered approach to care, creating an environment for continuous innovation and collaboration.
As the demand for effective mental, emotional, and physical support increases, companies are prompted to adapt their strategies to capture market share while focusing on patient outcomes.Genexine is prominent in the South Korea Cancer Supportive Care Market, leveraging its research capabilities and innovative therapies to make significant contributions to cancer care. The company's strengths lie in its developed products that focus on the biological mechanisms underlying cancer and supportive therapies that improve patient outcomes. With a strong emphasis on research and collaboration with local healthcare institutions, Genexine has established a solid footing within the market. Their focus on improving the quality of life for cancer patients highlights their commitment to patient-centric care, enhancing their reputation and market presence.
As the company continues to advance its products and forge partnerships, it plays a vital role in positioning supportive care as an essential aspect of comprehensive cancer treatment in South Korea.Eone Diagnomics Genome Center holds a key position in the South Korea Cancer Supportive Care Market, offering an array of services that are pivotal in personalized cancer care.
The company specializes in genomic testing and data-driven approaches to understand the complexities of cancer, which enables tailored supportive care strategies for patients. Eone Diagnomics has established a robust market presence through its innovative testing solutions that not only support cancer diagnosis but also enhance the management of treatment-related side effects. Their strengths include advanced technological capabilities and a deep understanding of genetic factors influencing cancer treatment. The company actively engages in collaborations and strategic alliances that enhance its market reach and expertise. By focusing on integrating genomic insights into supportive care, Eone Diagnomics sets itself apart in the competitive landscape, supporting its goal of improving patient health outcomes through personalized care in the South Korean context.
Key Companies in the South Korea Cancer Supportive Care Market Include
South Korea Cancer Supportive Care Market Industry Developments
Recent developments in the South Korea Cancer Supportive Care Market have been notable, particularly with advancements in therapeutics and supportive treatments. Companies like Genexine and PharmAbcine are focusing on innovative oncology solutions that enhance patient quality of life during treatment. In recent months, Eone Diagnomics Genome Center has made strides in genomic research, potentially improving personalized medicine approaches in cancer care. In a significant merger in August 2023, Hanmi Pharmaceutical announced its acquisition of a biotech firm specializing in immunotherapy, which strengthens its position in the market.
Moving toward growth, Celltrion and LG Chem have reported considerable expansions in their product lines, reflecting a rise in market valuation that is positively impacting their operational capacity and investor confidence. Furthermore, the Korean government has committed to increasing funding for cancer research initiatives, demonstrating its commitment to advancing cancer care. The market has been influenced by ongoing innovations and investments from key players such as Samsung Biologics and SK Biopharmaceuticals, aiming to establish South Korea as a pivotal hub for cancer supportive therapies in the Asia-Pacific region.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 510.0(USD Million) |
| MARKET SIZE 2024 | 522.75(USD Million) |
| MARKET SIZE 2035 | 876.25(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.808% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Genexine, Eone Diagnomics Genome Center, PharmAbcine, Korea United Pharm, Salubris Biopharma, Ahngook Pharmaceuticals, Chugai Pharmaceutical, Celltrion, LG Chem, SK Biopharmaceuticals, Green Cross Corporation, Samsung Biologics, Hanmi Pharmaceutical, Medytox, Daewoong Pharmaceutical |
| SEGMENTS COVERED | Type, Application, Distribution Channel |
| KEY MARKET OPPORTUNITIES | Telehealth services expansion, Personalized nutrition programs, Psychological support services growth, Advanced pain management solutions, Integrative therapy options increase |
| KEY MARKET DYNAMICS | increasing cancer prevalence, rising healthcare expenditure, growing demand for holistic care, advancements in treatment options, supportive technology integration |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea Cancer Supportive Care Market is expected to be valued at 522.75 million USD in 2024.
By 2035, the market is projected to reach 876.25 million USD.
The expected CAGR for the market is 4.808% from 2025 to 2035.
In 2024, the Antiemetics segment is valued the highest at 150.0 million USD.
The market value for ESA is expected to reach 167.0 million USD in 2035.
Major players include Genexine, Celltrion, LG Chem, and Samsung Biologics.
The projected market size for G-CSFs is estimated at 200.0 million USD in 2035.
The Bisphosphonates segment is valued at 80.0 million USD in 2024.
Challenges include regulatory hurdles and competition among existing players.
The expected market size for Opioids is projected to reach 139.25 million USD in 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
